BioCentury
ARTICLE | Company News

Avexa infectious news

May 17, 2010 7:00 AM UTC

Avexa plans to reduce headcount and pursue strategic alternatives after discontinuing development of HIV candidate apricitabine. Avexa said it was unable to find a partner for the cytidine analog nucleoside reverse transcriptase inhibitor (NRTI), which was in Phase III testing. The company said strategic alternatives could include a merger, acquisition, in-licensing opportunities and other corporate initiatives. The headcount reduction will affect all areas of the company. Julian Chick resigned from the board and will step down as CEO on May 31. ...